nivolumab,ipilimumab
bms
['lba9025', 'lcsm,(-blcsm)', 'lung', 'scienceatbms', 'bms']
attending #asco22? don t miss the first landmark 5-year survival data from a phase 3 trial of first-line dual #immunotherapy in patients with metastatic non-small cell #lungcancer: poster session on june 6, lba9025: #lcsm. 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: